Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Q2 EPS Loss of $0.08
Tweet
Share
E-mailGet Alerts CYCC Hot Sheet
Price: $6.37 --0%
Financial Fact:
Total other income (expense): 77K
Today's EPS Names:
PMCB, PLCE, DOMO, More
Financial Fact:
Total other income (expense): 77K
Today's EPS Names:
PMCB, PLCE, DOMO, More
Join SI Premium – FREE
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) reported Q2 EPS of ($0.08), $0.03 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $200 thousand versus the consensus estimate of $190 thousand.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Medtronic (MDT) Tops Q1 EPS by 6c, Beats on Revenue; Offers FY27 EPS Guidance
- Autodesk (ADSK) Tops Q2 EPS by 18c, Beats on Revenue; Offers FY27 EPS Guidance
- HealthEquity (HQY) Tops Q2 EPS by 5c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
